Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€81.65

€81.65

0.860%
0.7
0.860%
€110.00
 
21:26 / Tradegate WKN: A2PSR2 / Name: BioNTech / Stock / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

BioNTech SE ADR Stock

BioNTech SE ADR gained 0.860% compared to yesterday.
Our community is currently high on BioNTech SE ADR with 13 Buy predictions and 3 Sell predictions.
With a target price of 110 € there is a positive potential of 34.72% for BioNTech SE ADR compared to the current price of 81.65 €.
Our community identified positive and negative aspects for BioNTech SE ADR stock for the coming years. 30 users see the criterium "Worthwhile Investment for the next years" as a plus for the BioNTech SE ADR stock. On the other hand our users think that "Non-cyclic/Cyclic" could be a problem in the future.

Pros and Cons of BioNTech SE ADR in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
S********** s********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-17

Upon initial examination, the financial statements of BioNTech, a company operating within the pharmaceutical industry, present a strong financial position. The company has exhibited consistent growth, maintaining robust liquidity, and profitability ratios.

Asset Growth: BioNTech's total assets increased significantly from €2.31 billion in 2020 to €23.28 billion in 2022, showcasing robust growth within just two years. Particularly, current assets, such as cash and receivables, have exhibited remarkable expansion.

Profitability: The company displays impressive net income figures, from €15.2 million in 2020 to a staggering €9.43 billion in 2022. This increase in net income underscores the company's ability to generate substantial profits.

Comments

Prediction Buy
Perf. (%) 3.38%
Target price 170.000
Change
Ends at 17.12.22

Target price set to 170.0
Show more

Buy BioNTech SE ADR
Show more

Buy BioNTech SE ADR
Show more